4.7 Article

Protectin D1 decreases pancreatitis severity in mice by inhibiting neutrophil extracellular trap formation

Journal

INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 94, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.intimp.2021.107486

Keywords

Acute pancreatitis; Protectin D1; Neutrophils; Neutrophil extracellular traps; PAD4

Funding

  1. Scientific Research Foundation of Qilu Hospital [QDKY2019RX11]

Ask authors/readers for more resources

The study demonstrates that PD1 alleviates acute pancreatitis by reducing early neutrophil infiltration and neutrophil extracellular trap formation.
Background: Docosahexaenoic acid-derived protectin D1 (PD1) was identified critical in the resolution of inflammation in vivo, where it modulates the innate immune response and stimulates resolution. Acute pancreatitis (AP) is characterized by local pancreatic inflammation with mild forms whereas systemic inflammation with severe forms. Herein we investigate the impact of PD1 in murine models of pancreatitis. Methods: Three independent AP models, which induced in male mice via intraperitoneal injection of caerulein, Larginine or pancreatic duct ligation, were used to confirm the protective effect of PD1. Infiltrations of neutrophils and macrophages in pancreas were detected by flow cytometry and immunohistochemistry. In vitro and in vivo neutrophil extracellular traps formation was detected by immunofluorescence staining. Expression of peptidylarginine deiminase 4 (PAD4) in activated neutrophils was evaluated by western blotting. Results: Systemic treatment with PD1 reduced serum activities of amylase and lipase, blunted the concentrations of tumor necrosis factor-alpha and interleukin-6 in serum and protected against pancreas histologic damage in three AP models. PD1 also prolonged the survival in the pancreatic duct ligation model. Moreover, pancreatic infiltration of neutrophils and neutrophil CitH3 expression were reduced after PD1 administration. In vitro studies revealed PD1 decreased supernatant cell-free DNA and CitH3 levels and downregulated PAD4 expression in mouse bone-marrow derived neutrophils. However, in the caerulein mice pretreated with GSK484 hydrochloride, an inhibitor of PAD4, PD1 treatment showed no more protective effect. Conclusions: PD1 ameliorates AP by decreasing early infiltration of neutrophils into the pancreas and neutrophil extracellular traps formation through PAD4. These results supply the foundation to consider PD1 as a therapy for AP.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available